Pliant Therapeutics, Inc.
PLRX
$1.38
-$0.09-6.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.50M | 14.53M | 14.26M | 15.02M | 15.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.94M | 53.32M | 62.01M | 60.64M | 52.39M |
| Operating Income | -58.94M | -53.32M | -62.01M | -60.64M | -52.39M |
| Income Before Tax | -56.17M | -49.73M | -57.76M | -55.85M | -46.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.17M | -49.73M | -57.76M | -55.85M | -46.96M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.17M | -49.73M | -57.76M | -55.85M | -46.96M |
| EBIT | -58.94M | -53.32M | -62.01M | -60.64M | -52.39M |
| EBITDA | -58.49M | -52.86M | -61.48M | -60.02M | -51.88M |
| EPS Basic | -0.92 | -0.82 | -0.95 | -0.93 | -0.78 |
| Normalized Basic EPS | -0.57 | -0.51 | -0.59 | -0.58 | -0.49 |
| EPS Diluted | -0.92 | -0.82 | -0.95 | -0.93 | -0.78 |
| Normalized Diluted EPS | -0.57 | -0.51 | -0.59 | -0.58 | -0.49 |
| Average Basic Shares Outstanding | 61.22M | 60.85M | 60.73M | 60.38M | 60.18M |
| Average Diluted Shares Outstanding | 61.22M | 60.85M | 60.73M | 60.38M | 60.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |